Oral Ibandronate in Postmenopausal Osteoporotic Women Alters Micromechanical Properties Independently of Changes in Mineralization View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-10-23

AUTHORS

Yohann Bala, Joseph Kohles, Robert R. Recker, Georges Boivin

ABSTRACT

Postmenopausal osteoporotic (PMOP) women treated with ibandronate had higher bone mineral density, lower bone turnover, and decreased incidence of new vertebral fractures. The aim of this study was to investigate the effect of daily or intermittent oral ibandronate on the degree of mineralization (DMB) of bone and microhardness (Hv) at the bone tissue and bone structural unit (BSU) levels. A total of 110 iliac biopsies were taken from patients treated for 22 or 34 months with an oral placebo (n = 36), 2.5 mg daily oral ibandronate (n = 40), or 20 mg intermittent oral ibandronate (n = 34). These regimens provide annual cumulative exposures (ACEs) that are about half of the therapeutic doses currently licensed for PMOP women. DMB and Hv were measured at the global level (i.e., cortical or cancellous) and the focal level (i.e., BSU). At the global level, DMB and its distribution were not significantly different from placebo after 22 and 34 months of treatment. Hv was significantly higher in the cortical, cancellous, and total bone after 22 and 34 months of ibandronate versus placebo for both regimens. At the focal level, DMB and Hv, measured simultaneously in 3,760 BSUs, were significantly and positively correlated in all groups (r = 0.59–0.65, p < 0.0001). However, analysis of covariance highlighted the differences in the y intercepts of the linear regressions of the placebo- and ibandronate-treated groups. We infer that a low ACE of oral ibandronate altered the bone micromechanical properties irrespective of changes in secondary mineralization. More... »

PAGES

6-14

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00223-012-9658-6

DOI

http://dx.doi.org/10.1007/s00223-012-9658-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1036510668

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23090678


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biopsy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density Conservation Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diphosphonates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fractures, Bone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ibandronic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteoporosis, Postmenopausal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Placebos", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Regression Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Reproducibility of Results", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Universit\u00e9 de Lyon, UMR 1033, 69008, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.25697.3f", 
          "name": [
            "INSERM UMR 1033 Equipe \u201cQualit\u00e9 Osseuse et Marqueurs Biologiques\u201d, Facult\u00e9 de M\u00e9decine Lyon Est, Claude Bernard (Domaine Laennec), Universit\u00e9 de Lyon, 7\u201311 rue Guillaume Paradin, 69372, Lyon Cedex 08, France", 
            "Universit\u00e9 de Lyon, UMR 1033, 69008, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bala", 
        "givenName": "Yohann", 
        "id": "sg:person.01260243176.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01260243176.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hoffmann-LaRoche, 07110, Nutley, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Hoffmann-LaRoche, 07110, Nutley, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kohles", 
        "givenName": "Joseph", 
        "id": "sg:person.01150513510.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150513510.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Osteoporosis Research Center, 68131, Omaha, NE, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Osteoporosis Research Center, 68131, Omaha, NE, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Recker", 
        "givenName": "Robert R.", 
        "id": "sg:person.016325222544.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016325222544.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e9 de Lyon, UMR 1033, 69008, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.25697.3f", 
          "name": [
            "INSERM UMR 1033 Equipe \u201cQualit\u00e9 Osseuse et Marqueurs Biologiques\u201d, Facult\u00e9 de M\u00e9decine Lyon Est, Claude Bernard (Domaine Laennec), Universit\u00e9 de Lyon, 7\u201311 rue Guillaume Paradin, 69372, Lyon Cedex 08, France", 
            "Universit\u00e9 de Lyon, UMR 1033, 69008, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boivin", 
        "givenName": "Georges", 
        "id": "sg:person.01270330331.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270330331.76"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1023/a:1018671823059", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017861302", 
          "https://doi.org/10.1023/a:1018671823059"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-005-2035-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041631602", 
          "https://doi.org/10.1007/s00198-005-2035-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1557/jmr.1999.0490", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053186687", 
          "https://doi.org/10.1557/jmr.1999.0490"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-003-1530-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045100855", 
          "https://doi.org/10.1007/s00198-003-1530-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-007-0462-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029822466", 
          "https://doi.org/10.1007/s00198-007-0462-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-007-0540-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051377661", 
          "https://doi.org/10.1007/s00198-007-0540-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-10-23", 
    "datePublishedReg": "2012-10-23", 
    "description": "Postmenopausal osteoporotic (PMOP) women treated with ibandronate had higher bone mineral density, lower bone turnover, and decreased incidence of new vertebral fractures. The aim of this study was to investigate the effect of daily or intermittent oral ibandronate on the degree of mineralization (DMB) of bone and microhardness (Hv) at the bone tissue and bone structural unit (BSU) levels. A total of 110 iliac biopsies were taken from patients treated for 22 or 34\u00a0months with an oral placebo (n\u00a0=\u00a036), 2.5\u00a0mg daily oral ibandronate (n\u00a0=\u00a040), or 20\u00a0mg intermittent oral ibandronate (n\u00a0=\u00a034). These regimens provide annual cumulative exposures (ACEs) that are about half of the therapeutic doses currently licensed for PMOP women. DMB and Hv were measured at the global level (i.e., cortical or cancellous) and the focal level (i.e., BSU). At the global level, DMB and its distribution were not significantly different from placebo after 22 and 34\u00a0months of treatment. Hv was significantly higher in the cortical, cancellous, and total bone after 22 and 34\u00a0months of ibandronate versus placebo for both regimens. At the focal level, DMB and Hv, measured simultaneously in 3,760 BSUs, were significantly and positively correlated in all groups (r\u00a0=\u00a00.59\u20130.65, p\u00a0<\u00a00.0001). However, analysis of covariance highlighted the differences in the y intercepts of the linear regressions of the placebo- and ibandronate-treated groups. We infer that a low ACE of oral ibandronate altered the bone micromechanical properties irrespective of changes in secondary mineralization.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00223-012-9658-6", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1089641", 
        "issn": [
          "0171-967X", 
          "1432-0827"
        ], 
        "name": "Calcified Tissue International", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "92"
      }
    ], 
    "keywords": [
      "annual cumulative exposure", 
      "intermittent oral ibandronate", 
      "oral ibandronate", 
      "higher bone mineral density", 
      "new vertebral fractures", 
      "daily oral ibandronate", 
      "low bone turnover", 
      "postmenopausal osteoporotic women", 
      "months of treatment", 
      "bone mineral density", 
      "oral placebo", 
      "osteoporotic women", 
      "vertebral fractures", 
      "iliac biopsies", 
      "bone turnover", 
      "therapeutic doses", 
      "mineral density", 
      "ibandronate", 
      "placebo", 
      "analysis of covariance", 
      "cumulative exposure", 
      "total bone", 
      "PMOP women", 
      "months", 
      "regimens", 
      "women", 
      "bone tissue", 
      "bone", 
      "degree of mineralization", 
      "linear regression", 
      "levels", 
      "biopsy", 
      "patients", 
      "group", 
      "incidence", 
      "doses", 
      "treatment", 
      "total", 
      "tissue", 
      "y-intercept", 
      "exposure", 
      "unit level", 
      "fractures", 
      "regression", 
      "aim", 
      "changes", 
      "half", 
      "differences", 
      "study", 
      "DMB", 
      "effect", 
      "turnover", 
      "secondary mineralization", 
      "global level", 
      "degree", 
      "analysis", 
      "intercept", 
      "focal level", 
      "covariance", 
      "mineralization", 
      "distribution", 
      "density", 
      "properties", 
      "HV", 
      "micromechanical properties", 
      "BSU", 
      "microhardness"
    ], 
    "name": "Oral Ibandronate in Postmenopausal Osteoporotic Women Alters Micromechanical Properties Independently of Changes in Mineralization", 
    "pagination": "6-14", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1036510668"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00223-012-9658-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23090678"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00223-012-9658-6", 
      "https://app.dimensions.ai/details/publication/pub.1036510668"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_575.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00223-012-9658-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00223-012-9658-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00223-012-9658-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00223-012-9658-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00223-012-9658-6'


 

This table displays all metadata directly associated to this object as RDF triples.

248 TRIPLES      21 PREDICATES      115 URIs      101 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00223-012-9658-6 schema:about N452991d7a1054dd58c6d7dde716aa5a6
2 N51093a61c2fc439c839849c834a5bf33
3 N67a7b2ffc9504036b5d5249b05432834
4 N6ce3c76983504a748246e22597dcdff5
5 N7ee51ac0b55a40ce900c923abf762984
6 N923fc871419f472f8b382275e1ce2a47
7 N9be7f960a24d429e9c5b62cb367d6294
8 Na15960ba81584fefbed2c2c1f4506aa4
9 Naa2e91e893d9459bad99c5cc07472a14
10 Nadecb30de460433aaf794c9d6a0c3f12
11 Nba0d155eff5b4e07a14b9eb5c7740fb1
12 Nee7acb047da84c629573c50ebcab65b7
13 Nf41bc094fe5b492b92a8ff267e306b55
14 Nf509e91dbc9e4cd1939dc884cd8fc17c
15 Nf6758749eff54451a7634015dd933de7
16 Nfc13bf5b16434a2b98750407c3a0f732
17 Nfc3bd38d0d6c4108b2a35e3c0a9d8e2a
18 anzsrc-for:11
19 anzsrc-for:1103
20 schema:author Neefcd255827f4e9d90ab4d38ac3d262c
21 schema:citation sg:pub.10.1007/s00198-003-1530-0
22 sg:pub.10.1007/s00198-005-2035-9
23 sg:pub.10.1007/s00198-007-0462-5
24 sg:pub.10.1007/s00198-007-0540-8
25 sg:pub.10.1023/a:1018671823059
26 sg:pub.10.1557/jmr.1999.0490
27 schema:datePublished 2012-10-23
28 schema:datePublishedReg 2012-10-23
29 schema:description Postmenopausal osteoporotic (PMOP) women treated with ibandronate had higher bone mineral density, lower bone turnover, and decreased incidence of new vertebral fractures. The aim of this study was to investigate the effect of daily or intermittent oral ibandronate on the degree of mineralization (DMB) of bone and microhardness (Hv) at the bone tissue and bone structural unit (BSU) levels. A total of 110 iliac biopsies were taken from patients treated for 22 or 34 months with an oral placebo (n = 36), 2.5 mg daily oral ibandronate (n = 40), or 20 mg intermittent oral ibandronate (n = 34). These regimens provide annual cumulative exposures (ACEs) that are about half of the therapeutic doses currently licensed for PMOP women. DMB and Hv were measured at the global level (i.e., cortical or cancellous) and the focal level (i.e., BSU). At the global level, DMB and its distribution were not significantly different from placebo after 22 and 34 months of treatment. Hv was significantly higher in the cortical, cancellous, and total bone after 22 and 34 months of ibandronate versus placebo for both regimens. At the focal level, DMB and Hv, measured simultaneously in 3,760 BSUs, were significantly and positively correlated in all groups (r = 0.59–0.65, p < 0.0001). However, analysis of covariance highlighted the differences in the y intercepts of the linear regressions of the placebo- and ibandronate-treated groups. We infer that a low ACE of oral ibandronate altered the bone micromechanical properties irrespective of changes in secondary mineralization.
30 schema:genre article
31 schema:isAccessibleForFree false
32 schema:isPartOf N492fdaadf5db45289eec43aeaaf3b2a5
33 N92960bf80ca14d7a9f7c0def47f6f762
34 sg:journal.1089641
35 schema:keywords BSU
36 DMB
37 HV
38 PMOP women
39 aim
40 analysis
41 analysis of covariance
42 annual cumulative exposure
43 biopsy
44 bone
45 bone mineral density
46 bone tissue
47 bone turnover
48 changes
49 covariance
50 cumulative exposure
51 daily oral ibandronate
52 degree
53 degree of mineralization
54 density
55 differences
56 distribution
57 doses
58 effect
59 exposure
60 focal level
61 fractures
62 global level
63 group
64 half
65 higher bone mineral density
66 ibandronate
67 iliac biopsies
68 incidence
69 intercept
70 intermittent oral ibandronate
71 levels
72 linear regression
73 low bone turnover
74 microhardness
75 micromechanical properties
76 mineral density
77 mineralization
78 months
79 months of treatment
80 new vertebral fractures
81 oral ibandronate
82 oral placebo
83 osteoporotic women
84 patients
85 placebo
86 postmenopausal osteoporotic women
87 properties
88 regimens
89 regression
90 secondary mineralization
91 study
92 therapeutic doses
93 tissue
94 total
95 total bone
96 treatment
97 turnover
98 unit level
99 vertebral fractures
100 women
101 y-intercept
102 schema:name Oral Ibandronate in Postmenopausal Osteoporotic Women Alters Micromechanical Properties Independently of Changes in Mineralization
103 schema:pagination 6-14
104 schema:productId N8594724a142742699834c049616f4aa5
105 Na06d999f55d74eb3961061957a271dc5
106 Nd68f8cdd38fc42dd89139062f59ec203
107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036510668
108 https://doi.org/10.1007/s00223-012-9658-6
109 schema:sdDatePublished 2022-08-04T17:00
110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
111 schema:sdPublisher Nad7175882e7f450b97d44cede80df380
112 schema:url https://doi.org/10.1007/s00223-012-9658-6
113 sgo:license sg:explorer/license/
114 sgo:sdDataset articles
115 rdf:type schema:ScholarlyArticle
116 N19176a77f9a2488fa86f91de9da1c729 rdf:first sg:person.01270330331.76
117 rdf:rest rdf:nil
118 N452991d7a1054dd58c6d7dde716aa5a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Administration, Oral
120 rdf:type schema:DefinedTerm
121 N492fdaadf5db45289eec43aeaaf3b2a5 schema:volumeNumber 92
122 rdf:type schema:PublicationVolume
123 N51093a61c2fc439c839849c834a5bf33 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Female
125 rdf:type schema:DefinedTerm
126 N5d1743719a664a8fb4685b7b8935e55b rdf:first sg:person.01150513510.45
127 rdf:rest N876676b2df8b49cd9f842e189d2c0503
128 N67a7b2ffc9504036b5d5249b05432834 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Middle Aged
130 rdf:type schema:DefinedTerm
131 N6ce3c76983504a748246e22597dcdff5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Bone Density Conservation Agents
133 rdf:type schema:DefinedTerm
134 N7ee51ac0b55a40ce900c923abf762984 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Regression Analysis
136 rdf:type schema:DefinedTerm
137 N8594724a142742699834c049616f4aa5 schema:name pubmed_id
138 schema:value 23090678
139 rdf:type schema:PropertyValue
140 N876676b2df8b49cd9f842e189d2c0503 rdf:first sg:person.016325222544.69
141 rdf:rest N19176a77f9a2488fa86f91de9da1c729
142 N923fc871419f472f8b382275e1ce2a47 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Biopsy
144 rdf:type schema:DefinedTerm
145 N92960bf80ca14d7a9f7c0def47f6f762 schema:issueNumber 1
146 rdf:type schema:PublicationIssue
147 N9be7f960a24d429e9c5b62cb367d6294 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Aged
149 rdf:type schema:DefinedTerm
150 Na06d999f55d74eb3961061957a271dc5 schema:name dimensions_id
151 schema:value pub.1036510668
152 rdf:type schema:PropertyValue
153 Na15960ba81584fefbed2c2c1f4506aa4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Treatment Outcome
155 rdf:type schema:DefinedTerm
156 Naa2e91e893d9459bad99c5cc07472a14 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Placebos
158 rdf:type schema:DefinedTerm
159 Nad7175882e7f450b97d44cede80df380 schema:name Springer Nature - SN SciGraph project
160 rdf:type schema:Organization
161 Nadecb30de460433aaf794c9d6a0c3f12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Bone Density
163 rdf:type schema:DefinedTerm
164 Nba0d155eff5b4e07a14b9eb5c7740fb1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Osteoporosis, Postmenopausal
166 rdf:type schema:DefinedTerm
167 Nd68f8cdd38fc42dd89139062f59ec203 schema:name doi
168 schema:value 10.1007/s00223-012-9658-6
169 rdf:type schema:PropertyValue
170 Nee7acb047da84c629573c50ebcab65b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Double-Blind Method
172 rdf:type schema:DefinedTerm
173 Neefcd255827f4e9d90ab4d38ac3d262c rdf:first sg:person.01260243176.80
174 rdf:rest N5d1743719a664a8fb4685b7b8935e55b
175 Nf41bc094fe5b492b92a8ff267e306b55 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Humans
177 rdf:type schema:DefinedTerm
178 Nf509e91dbc9e4cd1939dc884cd8fc17c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Diphosphonates
180 rdf:type schema:DefinedTerm
181 Nf6758749eff54451a7634015dd933de7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Ibandronic Acid
183 rdf:type schema:DefinedTerm
184 Nfc13bf5b16434a2b98750407c3a0f732 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Reproducibility of Results
186 rdf:type schema:DefinedTerm
187 Nfc3bd38d0d6c4108b2a35e3c0a9d8e2a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Fractures, Bone
189 rdf:type schema:DefinedTerm
190 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
191 schema:name Medical and Health Sciences
192 rdf:type schema:DefinedTerm
193 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
194 schema:name Clinical Sciences
195 rdf:type schema:DefinedTerm
196 sg:journal.1089641 schema:issn 0171-967X
197 1432-0827
198 schema:name Calcified Tissue International
199 schema:publisher Springer Nature
200 rdf:type schema:Periodical
201 sg:person.01150513510.45 schema:affiliation grid-institutes:grid.418158.1
202 schema:familyName Kohles
203 schema:givenName Joseph
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150513510.45
205 rdf:type schema:Person
206 sg:person.01260243176.80 schema:affiliation grid-institutes:grid.25697.3f
207 schema:familyName Bala
208 schema:givenName Yohann
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01260243176.80
210 rdf:type schema:Person
211 sg:person.01270330331.76 schema:affiliation grid-institutes:grid.25697.3f
212 schema:familyName Boivin
213 schema:givenName Georges
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270330331.76
215 rdf:type schema:Person
216 sg:person.016325222544.69 schema:affiliation grid-institutes:None
217 schema:familyName Recker
218 schema:givenName Robert R.
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016325222544.69
220 rdf:type schema:Person
221 sg:pub.10.1007/s00198-003-1530-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045100855
222 https://doi.org/10.1007/s00198-003-1530-0
223 rdf:type schema:CreativeWork
224 sg:pub.10.1007/s00198-005-2035-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041631602
225 https://doi.org/10.1007/s00198-005-2035-9
226 rdf:type schema:CreativeWork
227 sg:pub.10.1007/s00198-007-0462-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029822466
228 https://doi.org/10.1007/s00198-007-0462-5
229 rdf:type schema:CreativeWork
230 sg:pub.10.1007/s00198-007-0540-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051377661
231 https://doi.org/10.1007/s00198-007-0540-8
232 rdf:type schema:CreativeWork
233 sg:pub.10.1023/a:1018671823059 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017861302
234 https://doi.org/10.1023/a:1018671823059
235 rdf:type schema:CreativeWork
236 sg:pub.10.1557/jmr.1999.0490 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053186687
237 https://doi.org/10.1557/jmr.1999.0490
238 rdf:type schema:CreativeWork
239 grid-institutes:None schema:alternateName Osteoporosis Research Center, 68131, Omaha, NE, USA
240 schema:name Osteoporosis Research Center, 68131, Omaha, NE, USA
241 rdf:type schema:Organization
242 grid-institutes:grid.25697.3f schema:alternateName Université de Lyon, UMR 1033, 69008, Lyon, France
243 schema:name INSERM UMR 1033 Equipe “Qualité Osseuse et Marqueurs Biologiques”, Faculté de Médecine Lyon Est, Claude Bernard (Domaine Laennec), Université de Lyon, 7–11 rue Guillaume Paradin, 69372, Lyon Cedex 08, France
244 Université de Lyon, UMR 1033, 69008, Lyon, France
245 rdf:type schema:Organization
246 grid-institutes:grid.418158.1 schema:alternateName Hoffmann-LaRoche, 07110, Nutley, NJ, USA
247 schema:name Hoffmann-LaRoche, 07110, Nutley, NJ, USA
248 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...